Inducible Hepatic-Associated Lymphoid Tissue (iHALT): generating and maintaining long-lived plasma cells
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
It has long been evasive why strictly hepatotropic viruses, such as hepatitis C virus (HCV), have been associated with the generation of delayed antibody responses that are of relatively poor quality to other, more systemic infections. Studies to date investigating antiviral adaptive immune priming within the liver have been hindered by lack of a natural, biologically relevant small animal model of viral infection exclusively restricted to hepatocytes. In this proposal, we will accordingly use the HGV-related rodent hepacivirus (RHV) recently discovered by our team, which possesses several similarities to its genetic relative, including strict liver tropism, conserved replication dependence on miR-122 interaction with the viral 5' UTR, identical genomic organizational structure and polyprotein cleavage pattern, and the propensity to cause chronic infection with fibrosis and hepatocellular carcinoma tumorigenesis. Our preliminary identification of robust antibody-secreting cell (ASC) responses, both total lgG and those targeting the envelope glycoprotein E2, almost exclusively arising within the liver during both human HCV and murine RHV infection, served as the rational impetus for further investigation of how, when, and where such responses are generated. The secondary lymphoid organ (SLO) dormancy accompanying such strong ASC responses within the liver alongside their durable maintenance therein by putative cognate anchoring pairs, many of which are also critical for tethering of long-lived plasma cells (LLPCs) to stromal niches in bone marrow, collectively suggest that the liver may serve as a site conducive to both the local generation and perpetual maintenance thereafter of LLPCs during strictly hepatotropic viral infection. As our recently published findings demonstrate that viral-specific lgG is critical for viral resolution, the development of chronic infection and HCC tumors in its absence suggests that generation of plausibly locally generated humoral responses within the liver at sites of virus-induced tertiary lymphoid structures, hereafter denoted as inducible Hepatic-Associated Lymphoid Tissue (iHALT), likely serve an important functional role. The survival of LLPCs residing in the liver 1.5 years post-clearance in these mice represents a unique scenario in which the liver may also provide a suitable niche for these cells, contrary to the canonical paradigm in which the bone marrow or select SLO circumstances are exclusively capable of fostering such an environment. We propose to mechanistically determine the signaling prerequisites responsible for driving this local, successful antiviral antibody response within the liver (Aim 1) as well as the cues instructing putatively locally derived progenies to be retained directly adjacent to their generative origins (Aim 2). Understanding these processes would significantly enhance our understanding of the relationship between hepatotropic viruses capable of suppressing SLOs in a state of functional dormancy with humoral responses plausibly being housed ectopically at extra lymphoid sites. Further, these studies would likely yield important insights capable of influencing the current paradigm of durable antibody responses in antigen free settings, specifically exploring a potentially novel niche site conducive to LLPC survival within the liver.
Grant Summary
Inducible Hepatic-Associated Lymphoid Tissue (iHALT): generating and maintaining long-lived plasma cells is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $923K for university, nonprofit, healthcare org. Applications are due 2031-01-31 (open). Check eligibility and apply with FindGrants.
Focus Areas
Eligibility
How to Apply
Up to $923K
2031-01-31
- 1Confirm your organization is eligible for Inducible Hepatic-Associated Lymphoid Tissue (iHALT): generating and maintaining long-lived plasma cells from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Inducible Hepatic-Associated Lymphoid Tissue (iHALT): generating and maintaining long-lived plasma cells: Frequently Asked Questions
Who is eligible for the Inducible Hepatic-Associated Lymphoid Tissue (iHALT): generating and maintaining long-lived plasma cells?
Inducible Hepatic-Associated Lymphoid Tissue (iHALT): generating and maintaining long-lived plasma cells is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Inducible Hepatic-Associated Lymphoid Tissue (iHALT): generating and maintaining long-lived plasma cells provide?
Inducible Hepatic-Associated Lymphoid Tissue (iHALT): generating and maintaining long-lived plasma cells provides up to $923K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Inducible Hepatic-Associated Lymphoid Tissue (iHALT): generating and maintaining long-lived plasma cells deadline?
Applications for Inducible Hepatic-Associated Lymphoid Tissue (iHALT): generating and maintaining long-lived plasma cells are due 2031-01-31 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Inducible Hepatic-Associated Lymphoid Tissue (iHALT): generating and maintaining long-lived plasma cells?
To apply for Inducible Hepatic-Associated Lymphoid Tissue (iHALT): generating and maintaining long-lived plasma cells, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.